to 64.5%) had histologically confirmed gestational trophoblastic disease. Assuming the approximation that there was no additional GTD in patients with negative scans who did not have histological tissue for analysis, the sensitivity of ultrasound was 70.00% (95% CI 61.99% to 77.20%) with a specificity of 99.88 % (95% CI 99.85% to 99.91%). The likelihood ratio for GTD after a positive ultrasound was 602.24, with a post-test probability of 0.548. Considering molar pregnancies alone, 61/69 (88.4%, 95% CI 78.5 to 94.3%) of complete moles were suspected on ultrasound preoperatively, compared with 40/74 (54.1%, 95% CI 42.8 to 64.9%) of partial moles. Conclusions: Our study supports the data published from other units showing that USS has a high sensitivity for the diagnosis of complete molar pregnancy. The diagnostic accuracy of partial moles is lower, but with a better than reported in the past. Patients with early pregnancy failure (anembryonic or early fetal demise, Crown-rump length 7-33mm) and vaginal bleeding were recruited from the emergency ward of the department of obstetrics and gynecology, Skane University Hospital, Malmö, Sweden and randomly allocated to either expectant care or 800μg of misoprostol vaginally. Patients were evaluated clinically and by ultrasound until complete evacuation of the uterus. Follow-up visits were planned at 10, 17, 24 and 31 days. Dilatation and evacuation was performed if miscarriage was not complete <31 days, or earlier on patient's request, or if there was excessive bleeding. Main outcome measure: Number of patients with complete miscarriage <10 days. Clinical Trials NCT01033903. Results: 94 patients were randomised to misoprostol and 95 to expectant care. After exclusion of 3 patients and withdrawal of consent by 2 patients 184 patients (n=94, n=90) were left to intention to treat analysis. After 10 days complete miscarriage was achieved in 66 % of the patients treated with misoprostol and in 43% of the patients with expectant management. 2 patients from each group underwent emergency D&E because of bleeding <10 days (2.1% vs. 2.2%). After 31 days of observation the rate of complete miscarriage was 86% in the misoprostol group and 61% in the expectant group. The number of D&E's on patient's request was higher in the expectantly managed group (17% vs. 3%) as was the number of patients making out of protocol visits (56% vs. 29%).
Conclusions:
Vaginal misoprostol is more effective than expectant management of early pregnancy failure with vaginal bleeding with regard to complete evacuation of the uterus. Objectives: To compare systemic and local ultrasound-guided methotrexate (MTX) therapy in uterine ectopic pregnancies regarding the β-hCG clearance. Methods: Retrospective data of forty-six women with uterine ectopic pregnancies (Caesarean scar, cervical, interstitial pregnancy) was evaluated. Patients were scanned and received either surgical treatment, MTX or expectant management. MTX was applied systemically intramuscularly or locally via ultrasound-guided injection. Primary endpoint was the β-hCG clearance duration in days. In order to investigate, whether the management (systemic MTX or local MTX) has a significant impact on the β-hCG clearance duration, a Wilcoxon Test at significance level = 0,05 was conducted. In order to investigate the effect of the management (systemic MTX or local MTX) on adverse effects (bleeding, pain, necessary interventional surgery), Fisher's exact tests were conducted. Results: Forty-six patients were diagnosed with uterine ectopic pregnancy (24 Caesarean scar, 17 interstitial, 5 cervical pregnancies). Of these, two were treated with expectant management, 39 with MTX (15 systemic; 24 local) and five were treated surgically.
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There was a significant difference in β-hCG clearance duration when comparing local and systemic MTX treatment (mean 66,82 days; 35,25 days respectively; p=0,004).
There was no statistically significant difference between local versus systemic MTX regarding the occurrence of bleeding (p=0,376), pain (p=0,146) or interventional surgery (p=0,631). However, we could observe a trend towards higher occurrence of bleeding and pain in the local MTX treatment group, and higher occurrence of subsequent surgery in the systemic MTX group. Conclusions: Patients who received local MTX showed a significantly longer β-hCG clearance duration compared to patients who received systemic MTX treatment (mean difference 26,5 days). There was no statistically significant difference of adverse effects (bleeding, pain, subsequent surgery) between both groups.
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Rates of spontaneous pregnancy loss and ovulation-implantation interval within a prospective pre-conception cohort 
